First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Razak Albiruni R. Abdul; Mau-Soerensen Morten; Gabrail Nashat Y.; Gerecitano John F.; Shields Anthony F.; Unger Thaddeus J.; Saint-Martin Jean R.; Carlson Robert; Landesman Yosef; McCauley Dilara; Rashal Tami; Lassen Ulrik; Kim Richard; Stayner Lee-Anne; Mirza Mansoor R.; Kauffman Michael; Shacham Sharon; Mahipal Amit

首页> 外文期刊>Journal of Clinical Oncology >First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

【24h】

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

机译：先进一类，先进的先进出口选择性抑制剂，核导出患者的先进阶段，术语

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第34期|共11页
作者
Razak Albiruni R. Abdul; Mau-Soerensen Morten; Gabrail Nashat Y.; Gerecitano John F.; Shields Anthony F.; Unger Thaddeus J.; Saint-Martin Jean R.; Carlson Robert; Landesman Yosef; McCauley Dilara; Rashal Tami; Lassen Ulrik; Kim Richard; Stayner Lee-Anne; Mirza Mansoor R.; Kauffman Michael; Shacham Sharon; Mahipal Amit;
展开▼
作者单位

Princess Margaret Canc Ctr Toronto ON Canada;

Rigshosp Copenhagen Denmark;

Gabrail Canc Inst Canton OH USA;

Weill Cornell Med Coll Mem Sloan Kettering Canc Ctr New York NY USA;

Wayne State Univ Karmanos Canc Inst Detroit MI USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Rigshosp Copenhagen Denmark;

H Lee Moffitt Canc Ctr &

Res Inst Tampa FL USA;

Princess Margaret Canc Ctr Toronto ON Canada;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

H Lee Moffitt Canc Ctr &

Res Inst Tampa FL USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors [J] . Razak Albiruni R. Abdul, Mau-Soerensen Morten, Gabrail Nashat Y., Journal of Clinical Oncology . 2016,第34期

机译：Selinexor（一种核出口的选择性抑制剂）在晚期实体瘤患者中的一流，首次人类I期研究
2. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma (vol 34, pg 3166, 2016) [J] . Gounder M. M. Journal of Clinical Oncology . 2017,第7期

机译：Selinexor，核导出一流抑制剂的硒蛋白抑制剂（Vol 34，PG 3166,2016）的核核抑制剂综合征抑制剂研究
3. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma [J] . Gounder Mrinal M., Zer Alona, Tap William D., Journal of Clinical Oncology . 2016,第26期

机译：Selinexor（一种先进的核输出抑制剂）在晚期难治性骨或软组织肉瘤患者中的IB期研究
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. First-in-Class First-in-Human Phase I Study of Selinexor a Selective Inhibitor of Nuclear Export in Patients With Advanced Solid Tumors [O] . Albiruni R. Abdul Razak, Morten Mau-Soerensen, Nashat Y. Gabrail, -1

机译：Selinexor（一种核出口的选择性抑制剂）在晚期实体瘤患者中的一流首次人类I期研究
7. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors [O] . Richard D. Baird, Constanza Linossi, Mark Middleton, 2021

机译：第一阶段I研究MP0250，是靶向VEGF和HGF的一流的Darpin毒品候选者，在先进的实体瘤患者中

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

摘要

著录项

相似文献

相关主题

期刊订阅